Breast Cancer
Brain Tumor
Cervical Cancer
HIV
7/23/2007/25
Science.
2005 Jun 3;308(5727):1477-80. Rickert M, Wang
X, Boulanger MJ, Goriatcheva N, Garcia
KC. Departments of Microbiology
and Immunology, and Structural Biology, Stanford University School of
Medicine, 299 Campus Drive, Fairchild D319, Stanford, CA 94305-5124, USA. Interleukin-2 (IL-2) is an immunoregulatory cytokine that binds sequentially to
the alpha (IL-2Ralpha), beta (IL-2Rbeta), and common gamma chain (gammac) receptor subunits. Here we present the 2.8
angstrom crystal structure of a complex between human IL-2 and IL-2Ralpha,
which interact in a docking mode distinct from that of other cytokine
receptor complexes. IL-2Ralpha is composed of strand-swapped
"sushi-like" domains, unlike the classical cytokine receptor
fold. As a result of this domain swap, IL-2Ralpha uses a composite surface
to dock into a groove on IL-2 that also serves as a binding site for
antagonist drugs. With this complex, we now have representative structures
for each class of hematopoietic cytokine
receptor-docking modules. PMID: 15933202 [PubMed
- indexed for MEDLINE] Int Immunopharmacol.
2006 Jun;6(6):1034-8. Epub
2006 Feb 3. Int Immunopharmacol.
2006 Jun;6(6):1034-8. Epub
2006 Feb 3. Science.
2005 Jun 3;308(5727):1477-80. Rickert M, Wang
X, Boulanger MJ, Goriatcheva N, Garcia
KC. Departments of Microbiology
and Immunology, and Structural Biology, Stanford University School of
Medicine, 299 Campus Drive, Fairchild D319, Stanford, CA 94305-5124, USA. Interleukin-2 (IL-2) is an immunoregulatory cytokine that binds sequentially to
the alpha (IL-2Ralpha), beta (IL-2Rbeta), and common gamma chain (gammac) receptor subunits. Here we present the 2.8
angstrom crystal structure of a complex between human IL-2 and IL-2Ralpha,
which interact in a docking mode distinct from that of other cytokine
receptor complexes. IL-2Ralpha is composed of strand-swapped
"sushi-like" domains, unlike the classical cytokine receptor
fold. As a result of this domain swap, IL-2Ralpha uses a composite surface
to dock into a groove on IL-2 that also serves as a binding site for
antagonist drugs. With this complex, we now have representative structures
for each class of hematopoietic cytokine
receptor-docking modules. PMID: 15933202 [PubMed
- indexed for MEDLINE] The effect of therapeutic hypothermia on the
expression of inflammatory response genes following moderate traumatic
brain injury in the rat. genes
and may target more delayed responses underlying the secondary damage
following TBI. ICAM-1 gene expression in endothelial cells: Effects on the
inhibition of STAT3 phosphorylation. Bradykinin mimics ischemic
preconditioning by generating reactive oxygen species (ROS). To identify
intermediate steps leading to ROS generation, rabbit cardiomyocytes
were incubated in reduced MitoTracker Red that
becomes fluorescent after exposure to ROS. Fluorescence intensity in
treated cells was expressed as % of that in paired untreated cells. Bradykinin (500nM) caused 51+/-16% increase in ROS
generation (p<0.001). Co-incubation with either bradykinin
B2 receptor blocker HOE140 (5 micro M) or free radical scavenger
N-(2-mercaptopropionyl) glycine (1mM) prevented
this increase confirming the response was receptor-mediated and ROS were
actually being measured. Closing mitochondrial KATP (mKATP)channels with 5-hydroxydecanoate (5HD, 1mM) prevented
increased ROS generation. Bradykinin-induced ROS
generation was blocked by L-NAME (200 micro M) implicating nitric oxide as
an intermediate. Blockade of guanylyl cyclase with ODQ (10 micro M) aborted bradykinin-induced ROS generation, but not that from diazoxide, a direct opener of mKATP
channels. The PKG blocker 8-Br-cGMPS (25 micro M)
eliminated bradykinin's effect. Conversely,
direct activation of PKG with 8-pCPT-cGMP (100 micro M) increased ROS
generation (39+/-15%, p<0.004) similar to bradykinin.
This increase was blocked by 5HD. Finally, the nitric oxide donor SNAP (1
micro M)increased ROS by 34+/-6%. This increase
was also blocked by 5HD. In intact rabbit hearts bradykinin
(400nM) decreased infarction from 30.5+/-3.0% of the risk zone in control
hearts to 11.9+/-1.4% (p<0.01). This protection was aborted by either
L-NAME (200 micro M) or ODQ (2 micro M)(35.4+/-5.7%
and 30.4+/-3.0% infarction, resp., pNS vs control). Hence, bradykinin preconditions through receptor-mediated
production of nitric oxide which activates guanylyl
cyclase. The resulting cGMP
activates PKG that opens mKATP. Subsequent
release of ROS triggers cardioprotection.
The structure of
interleukin-2 complexed with its alpha receptor.
IL-2 increased RANTES production and CD25
expression in cultured PBMCs only from
antiretroviral treated HIV-1+ patients with detectable viral loads.
Lozano
JM, Kindelan JM, Cabello A, Gonzalez
R, Solana
R, Pena
J.
Department of Immunology, Hospital "Reina
Sofia", University of Cordoba, Spain; Department of Virology, Pasteur
Institute of Paris, France.
In order to better understand the possible beneficial effects of
intermittent IL-2 treatment as complement of antiretroviral therapy in
HIV-1+ patients, we have measured the levels of RANTES in the supernatants
and the CD25 expression in cultured PBMCs
obtained from HIV-1+ individuals in presence of IL-2. The results showed a
significant increases in RANTES production and in the expression of CD25+
in the cultures with IL-2 of PBMC obtained from HIV-1+ patients with a
detectable viral load in comparison with both, HIV-1+ patients with no
detectable viral loads and with healthy individuals. These results suggest
that therapeutic IL-2 administered in addition to highly active
anti-retroviral therapy (HAART) may contribute to increase the effect of
this therapy by rising both RANTES production and CD25 expression only in
HIV-1+ patients with detectable viral loads.
PMID: 16644491 [PubMed - in process]
IL-2 increased RANTES production and CD25
expression in cultured PBMCs only from
antiretroviral treated HIV-1+ patients with detectable viral loads.
Lozano
JM, Kindelan JM, Cabello A, Gonzalez
R, Solana
R, Pena
J.
Department of Immunology, Hospital "Reina
Sofia", University of Cordoba, Spain; Department of Virology, Pasteur
Institute of Paris, France.
In order to better understand the possible beneficial effects of
intermittent IL-2 treatment as complement of antiretroviral therapy in
HIV-1+ patients, we have measured the levels of RANTES in the supernatants
and the CD25 expression in cultured PBMCs obtained
from HIV-1+ individuals in presence of IL-2. The results showed a
significant increases in RANTES production and in the expression of CD25+
in the cultures with IL-2 of PBMC obtained from HIV-1+ patients with a
detectable viral load in comparison with both, HIV-1+ patients with no
detectable viral loads and with healthy individuals. These results suggest
that therapeutic IL-2 administered in addition to highly active
anti-retroviral therapy (HAART) may contribute to increase the effect of
this therapy by rising both RANTES production and CD25 expression only in
HIV-1+ patients with detectable viral loads.
PMID: 16644491 [PubMed - in process]
The structure of
interleukin-2 complexed with its alpha receptor.
Truettner
JS, Suzuki T, Dietrich WD.
Department of Neurological Surgery, The Neurotrauma
Research Center, The Miami Project to Cure Paralysis, University of Miami
School of Medicine, Miami, FL 33136, USA.
Traumatic brain injury (TBI) initiates a cascade of cellular and molecular
responses including both pro- and anti-inflammatory. Although
post-traumatic hypothermia has been shown to improve outcome in various
models of brain injury, the underlying mechanisms responsible for these
effects have not been clarified. In this study, inflammation cDNA arrays and semi-quantitative RT-PCR were used to
detect genes that are differentially regulated after TBI. In addition, the
effect of post-traumatic hypothermia on the expression of selective genes
was also studied. Rats (n = 6-8 per group) underwent moderate
fluid-percussion (F-P) brain injury with and without hypothermic treatment
(33 degrees C/3 h). RNA from 3-h or 24-h survival was analyzed for the
expression of IL1-beta, IL2, IL6, TGF-beta2, growth-regulated oncogene (GRO), migration inhibitory factor (MIF), and
MCP (a transcription factor). The interleukins IL-1beta, IL-2, and IL-6 and
TGF-beta and GRO were strongly upregulated early
and transiently from 2- to 30-fold over sham at 3 h, with normalization by
24 h. In contrast, the expressions of MIF and MCP were both reduced by TBI
compared to sham. Post-traumatic hypothermia had no significant effect on
the acute expression of the majority of genes investigated. However, the
expression of TGF-beta2 at 24 h was significantly reduced by temperature
manipulation. The mechanism by which post-traumatic hypothermia is
protective may not involve a general genetic response of the inflammatory
genes. However, specific genes, including TGF-beta2, may be altered and
effect cell death mechanisms after TBI. Hypothermia differentially
regulates certain
PMID: 15922484 [PubMed - in process]
erase chain
reaction in unstimulated PBMC and in PBMC
incubated for 4h in the presence of concanavalin
A (ConA) or phorbol
12-myristate 13-acetate plus ionomycin (PMA/I).
Compared to unstimulated
cells, stimulation with ConA and PMA/I increased
the IL2 mRNA transcription in average by 300- and 20-fold, respectively.
Nevertheless, no significant differences in IL2 transcription between the
genotypes could be detected. These findings were confirmed by band shift
studies using different oligonucleotides
containing variations of the potential binding motif, which showed no
differences in the gel mobility after incubation with nuclear extract
containing GATA-3. The obtained results argue against an impact of this
polymorphism on the IL2 transcription and the genetic disease resistance in
sheep.
Resveratrol suppresses IL-6-induced
Wung
BS, Hsu MC, Wu CC, Hsieh CW.
Department of Applied Microbiology,
Resveratrol, a polyphenolic
phytoaxelin present in red wine, has been
suggested to protect against atherosclerosis and cardiovascular disease
because of its antioxidant effects. Intercellular adhesion molecule
(ICAM-1), induced by cytokines, has been hypothesized to play a role in the
early events during atherosclerosis. In this study we tested the effects of
resveratrol upon both IL-6-induced ICAM-1 gene
expression and its underlying signaling pathways in endothelial cells (ECs). Resveratrol was found
to inhibit both TNFalpha- and IL-6-induced ICAM-1
gene expression at the promoter, transcriptional and protein levels. Resveratrol also abrogates the tyr705 phosphorylation of STAT3 in IL-6-treated ECs, in a dose- and time-dependent manner. Although quercetin had similar effects, resveratrol
showed higher inhibitory properties following 2-4 h pretreatments. Resveratrol has been shown to induce the activity of
endothelial nitric oxide synthase (eNOS) and increase NO production. Consistent with this,
the treatment of ECs with a NO donor (SNAP)
reduces IL-6-induced STAT3 phosphorylation.
Conversely, exposure of ECs to a NOS inhibitor
reversed the effects of resveratrol upon
IL-6-induced STAT3 phosphorylation. Furthermore, ECs transfected with
constitutively active Rac1 (RacV12) showed increases in ICAM-1 promoter
activity, intracellular reactive oxygen species (ROS) levels and STAT3 phosphorylation, and these increases were attenuated by
resveratrol treatment. In summary, we demonstrate
for the first time that resveratrol inhibits
IL-6-induced ICAM-1 gene expression, in part, by interfering with Rac-mediated pathways via the attenuation of STAT3 phosphorylation. This study therefore provides
important new insights that may contribute to the proposed beneficial effects
of resveratrol in endothelial responses to
cytokines during inflammation.
PMID: 16150460 [PubMed - as supplied by
publisher]